Lafayette, R. Et Al. 2024. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney International , vol.105, no.6 , 1306-1315.

Lafayette, R., Barbour, S., Israni, R., Wei, X., EREN, N., Floege, J., ... Jha, V.(2024). A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney International , vol.105, no.6, 1306-1315.

Lafayette, Richard Et Al. "A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy," Kidney International , vol.105, no.6, 1306-1315, 2024

Lafayette, Richard Et Al. "A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy." Kidney International , vol.105, no.6, pp.1306-1315, 2024

Lafayette, R. Et Al. (2024) . "A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy." Kidney International , vol.105, no.6, pp.1306-1315.

@article{article, author={Richard Lafayette Et Al. }, title={A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy}, journal={Kidney International}, year=2024, pages={1306-1315} }